Please login to the form below

Not currently logged in
Email:
Password:

Sanofi-aventis Q1 hit by H1N1

Sanofi-aventis has seen its first-quarter financial results hit by lack of flu vaccine and generic competition

Sanofi-aventis (SA) has reported a 16.1 per cent fall in net income to €2.2bn at CER for the first quarter of 2011.

The company posted a 5.2 per cent decline in first-quarter sales to €7.8bn in 2011, including €569m of sales lost in 2011 due to generic competition,.

However, excluding A/H1N1 sales its first-quarter sales rose by 0.1 per cent.

The company said emerging markets sales increased by 14.6 per cent (excluding A/H1N1 sales) to €2.4bn, exceeding the US and Western Europe, and accounted for 30.7 per cent of group sales.

Christopher A Viehbacher, CEO, S-A, said: "This quarter, the year-on-year comparison must take into account the absence of non-recurring A/H1N1 sales. I'm particularly satisfied with the performance of our growth platforms which were up 15.5 per cent (excluding A/H1N1) and now represent almost 60 per cent of group sales; these businesses have compensated for the impact of generic competition on net sales and represent the future of our company."

S-A's EPS was €1.66, down 16.1 per cent at CER. Excluding A/H1N1 sales, the decrease in business EPS was limited to 6.0 per cent at CER.

28th April 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Fendix

Fendix is the only NHS digital media network and it provides organisations, such as pharma, with unrivalled digital access to...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics